Publication | Closed Access
A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma
29
Citations
0
References
2019
Year
Hematological MalignancyAmg 176MedicineImmunologyImmune Checkpoint InhibitorOncologyRadiation OncologyPhase 1Cancer ResearchRefractory Multiple Myeloma
No additional data available for this publication yet. Check back later!